A landscape of driver mutations in melanoma

Cited by (1,006)

Items 901–1,000 of 1,006

1. Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
   Pierre Murchan, Cathal P. O’Brien, Shane O’Connell, Ciara S. McNevin, Anne‐Marie Baird, Orla M. Sheils, Pilib Ó Broin, Stephen P. Finn · 2021 · Diagnostics
2. Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis
   Jyoti Motwani, Michael Roger Eccles · 2021 · Genes
3. Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach
   Rahul Metri, Abhilash Mohan, Jérémie Nsengimana, Joanna Poźniak, Carmen Molina-Parı́s, Julia Newton‐Bishop, David Timothy Bishop, Nagasuma R Chandra · 2017 · Scientific Reports
4. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
   Ksenija Asić · 2015 · Critical Reviews in Oncology/Hematology
5. The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells
   Or‐Yam Revach, Sabina E. Winograd-Katz, Yardena Samuels, Benjamin Geiger · 2016 · Experimental Cell Research
6. [Ultraviolet A-induced DNA damage: role in skin cancer].
   Jean‐Claude Béani · 2014 · PubMed
7. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells
   Nazareno González, Georgina Alexandra Cardama, Maria Julieta Comin, Valeria Inés Segatori, Marina Pífano, Daniel F. Alonso, Daniel Eduardo Gomez, Pablo Lorenzano Menna · 2016 · Cellular Signalling
8. BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma
   Julia Chisholm, Jozef Suvada, Ira J. Dunkel, Michela Casanova, Weijiang Zhang, Natasha Ritchie, YounJeong Choi, Jane Park, Meghna Das Thakur, Stephen J. Simko et al. · 2018 · Pediatric Blood & Cancer
9. Pediatric patients with cutaneous melanoma: A European study
   Ines B. Brecht, Angela De Paoli, Gianni Bisogno, Daniel H. Orbach, Dominik T. Schneider, Ulrike Leiter, Sonja Offenmüller, Giovanni Cecchetto, Jan Krzysztof Godzinski, Ewa Bień et al. · 2018 · Pediatric Blood & Cancer
10. Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
    Lorena Incorvaia, Giuseppe Badalamenti, Gaetana Rinaldi, Juan Iovanna, Daniel Olive, Mirna Swayden, Lidia Terruso, Bruno Vincenzi, Fabio Fulfaro, Viviana Bazan et al. · 2019 · Therapeutic Advances in Medical Oncology
11. CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis
    C. Simbulan-Rosenthal, Ryan Dougherty, S. Vakili, Alexandra M. Ferraro, Li-Wei Kuo, Ryyan Alobaidi, Leala Aljehane, Anirudh Gaur, P. Sykora, E. Glasgow et al. · 2019 · Cancers
12. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling
    Zhengyun Zou, Qiuxiang Ou, Yu Ren, Qing Lv, Lanqun Qin, Lianjun Zhao, Shu Su, Xue Wu, Hua Bao, Ao Wang et al. · 2020 · Pigment Cell & Melanoma Research
13. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions
    Alberto S. Pappo, Valerie J. McPherson, Haitao Pan, Fang Wang, Lu Wang, Teresa S. Wright, Margaret Hussong, Dana Hawkins, Sue Creviston Kaste, Andrew M. Davidoff et al. · 2021 · Cancer
14. Mechanisms of Resistance to RAF Inhibition in Melanomas Harboring a BRAF Mutation
    Paul B. Chapman · 2013 · American Society of Clinical Oncology Educational Book
15. Real-Time Quantitative Detection of Ultraviolet Radiation Dose Based on Photochromic Hydrogel and Photo-Resistance
    Guo-Yu Wen, Xinglong Zhou, Xiaoyu Tian, Ting-Yuan Hu, Rui Xie, Xiao‐Jie Ju, Zhuang Liu, Dawei Pan, Wei Wang, Liang‐Yin Chu · 2022 · Chemistry of Materials
16. Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
    Irene Marchesi, Luigi Bagella · 2016 · World Journal of Clinical Oncology
17. Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications
    Megan R. Dreier, Jasmine Walia, Ivana L. de la Serna · 2024 · Epigenomes
18. STK19 drives transcription-coupled repair by stimulating repair complex stability, RNA Pol II ubiquitylation, and TFIIH recruitment
    Anisha R. Ramadhin, Shun-Hsiao Lee, Di Zhou, Anita Salmazo, Camila Gonzalo-Hansen, Marjolein van Sluis, Cindy M.A. Blom, Roel C. Janssens, Anja Raams, Dick H. W. Dekkers et al. · 2024 · Molecular Cell
19. C-RAF Mutations Confer Resistance to RAF Inhibitors
    Rajee Antony, Caroline M. Emery, Allison M. Sawyer, Levi A. Garraway · 2013 · Cancer Research
20. Understanding the Biology of Melanoma and Therapeutic Implications
    Ryan Joseph Sullivan, David E. Fisher · 2014 · Hematology/Oncology Clinics of North America
21. Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
    Inês Pires da Silva, Amel Salhi, Keith Michael Giles, Matjaž Vogelsang, Sung Won Han, Naı̈ma Ismaı̈li, Kevin P. Lui, Eric Michael Robinson, Melissa Ann Wilson, Richard L. Shapiro et al. · 2015 · Clinical Cancer Research
22. EZH2 as a mediator of treatment resistance in melanoma
    Jessamy C. Tiffen, Stuart J. Gallagher, Hsin‐Yi Tseng, Fabian V. Filipp, Barbara Fazekas de St Groth, Peter Hersey · 2016 · Pigment Cell & Melanoma Research
23. Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain
    Shuning He, Marc R. Mansour, Mark W. Zimmerman, Dong Hyuk Ki, Hillary M. Layden, Koshi Akahane, Evisa Gjini, Eric D. de Groh, Antonio R. Pérez‐Atayde, Shizhen Zhu et al. · 2016 · eLife
24. Biomarkers of genome instability and cancer epigenetics
    Adriana H. O. Reis, Fernando Regla Vargas, Bernardo Lemos · 2016 · Tumor Biology
25. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies
    Manfred Kunz, Michael Hölzel · 2017 · Cancer and Metastasis Reviews
26. ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment
    Chi‐Fen Chen, Rolando Ruiz, Priya Vasudeva, Francisco Espitia, Tatiana B. Krasieva, Sébastien M. de Feraudy, Bruce J. Tromberg, Sharon Huang, Chad P. Garner, Jie Wu et al. · 2017 · Cell Reports
27. Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
    Mathias Bernhardt, Daniel Novak, Yassen Assenov, Elias Orouji, Nathalie Knappe, Kasia Weina, Maike Reith, Lionel Larribère, Christoffer Gebhardt, Christoph Plass et al. · 2017 · Stem Cell Reports
28. Zebrafish in Translational Cancer Research: Insight into Leukemia, Melanoma, Glioma and Endocrine Tumor Biology
    Aurora Irene Idilli, Francesca Precazzini, Marina Mione, Viviana Anelli · 2017 · Genes
29. Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology
    Norberto Mancera, Keiran S.M. Smalley, Curtis Edward Margo · 2018 · Survey of Ophthalmology
30. Ensuring the Safety of Sunscreens, and Their Efficacy in Preventing Skin Cancers: Challenges and Controversies for Clinicians, Formulators, and Regulators
    Sharad P. Paul · 2019 · Frontiers in Medicine
31. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
    Melanoma Unit of Sassari (MUS), Antonella Manca, for the Italian Melanoma Intergroup (IMI), Panagiotis Paliogiannis, Maria Colombino, Milena Casula, Amelia Lissia, Gerardo Botti, Corrado Caracò, Paolo A. Ascierto et al. · 2019 · Journal of Translational Medicine
32. WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5–MDM2–p53 pathway
    Yumei Li, Yu Zhou, Bifei Li, Fan Chen, Weiyu Shen, Yusheng Lu, Chunlian Zhong, Chen Zhang, Huanzhang Xie, Vladimir L. Katanaev et al. · 2020 · Oncogene
33. Emerging strategies to treat rare and intractable subtypes of melanoma
    Gretchen Marie Alicea, Vito W. Rebecca · 2020 · Pigment Cell & Melanoma Research
34. Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
    Russell J. Diefenbach, Jenny Lee, Alexander Maxwell Menzies, Matteo Salvatore Carlino, Georgina Venetia Long, Robyn P.M. Saw, Julie R. Howle, Andrew John Spillane, Richard A. Scolyer, Richard F. Kefford et al. · 2020 · Cancers
35. Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity
    Daniel Pomeranz Krummel, Tahseen H. Nasti, Milota Kaluzová, Laura M. Kallay, Debanjan Bhattacharya, Johannes C. Melms, Benjamin Izar, Maxwell Xu, Andre J. Burnham, Taukir Ahmed et al. · 2020 · International Journal of Radiation Oncology*Biology*Physics
36. Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer
    Pratyusha Bala, Anurag Kumar Singh, Padmavathi Kavadipula, Viswakalyan Kotapalli, Radhakrishnan Sabarinathan, Murali Dharan Bashyam · 2020 · Oncogene
37. Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
    Yuran Qiu, Yuanhao Wang, Zong‐Tao Chai, Duan Ni, Xinyi Li, Jun Pu, Jie Chen, Jian Zhang, Shaoyong Lu, Chuan Lv et al. · 2021 · Acta Pharmaceutica Sinica B
38. IER2-induced senescence drives melanoma invasion through osteopontin
    L. Kyjacová, Rafael Saup, K. Rönsch, S. Wallbaum, Stefanie Dukowic-Schulze, Amelia Foss, Sandra D. Scherer, M. Rothley, A. Neeb, N. Grau et al. · 2021 · Oncogene
39. Ras and Rac1, Frequently Mutated in Melanomas, Are Activated by Superoxide Anion, Modulate Dnmt1 Level and Are Causally Related to Melanocyte Malignant Transformation
    Fernanda Molognoni, Fabiana Henriques Machado de Melo, Camila Tainah da Silva, Miriam Galvonas Jasiulionis · 2013 · PLoS ONE
40. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma
    Jianping Gui, Zhen Guo, Di Wu · 2022 · Journal of Translational Medicine
41. A comprehensive review on anticancer evaluation techniques
    Chetana Sanjai, Sushruta S. Hakkimane, Bharath Raja Guru, Santosh Laxman Gaonkar · 2023 · Bioorganic Chemistry
42. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
    Vipin Yadav, Shih-Hsun Chen, Yong Gong Yue, Sean G. Buchanan, Richard Paul Beckmann, Sheng-Bin Peng · 2014 · Pharmacology & Therapeutics
43. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma
    Romany A. N. Johnpulle, Douglas B. Johnson, J. Sosman · 2016 · Current Oncology Reports
44. Therapeutic implications of melanoma heterogeneity
    Stephanie J. Hachey, Alexander D. Boiko · 2016 · Experimental Dermatology
45. Loss of neural crest‐associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation
    Huizi Wu, Lionel Larribère, Qian Sun, Daniel Novak, Sachindra Sachindra, Karol Granados, Viktor Umansky, Jochen Sven Utikal · 2018 · International Journal of Cancer
46. Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells
    Oxana O. Ryabaya, A. A. Prokofieva, Roman Akasov, Dmitry A. Khochenkov, Marina Emelyanova, Sergey V. Burov, Марквичева Елена Арнольдовна, Andrey N. Inshakov, Е. В. Степанова · 2018 · Biomedicine & Pharmacotherapy
47. Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development
    Nashwa El Hadidy, Vladimir Nikolaevich Uversky · 2019 · International Journal of Molecular Sciences
48. The tumor genetics of acral melanoma: What should a dermatologist know?
    Bianca Tod, Johann W. Schneider, Anne M. Bowcock, Willem I. Visser, Maritha J. Kotze · 2020 · JAAD International
49. PPP6C Negatively Regulates STING-Dependent Innate Immune Responses
    Guoxin Ni, Zhe Ma, Jason P. Wong, Zhigang Zhang, Emily M. Cousins, Michael B. Major, Blossom Damania · 2020 · mBio
50. Transcriptional regulators and alterations that drive melanoma initiation and progression
    Romi Gupta, Radoslav Janoštiak, Narendra Wajapeyee · 2020 · Oncogene
51. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
    Wei Chong, Zhe Wang, Liang Shang, Shengtao Jia, Jin Liu, Zhen Fang, Fengying Du, Hao Wu, Yang Liu, Yang Chen et al. · 2020 · Molecular Therapy — Nucleic Acids
52. The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
    Lazaro Hiram Betancourt, Jeovanis Gil, Aniel Sánchez, Viktória Doma, Magdalena Kuras, Jimmy Rodriguez Murillo, Erika Velásquez, Uğur Çakır, Yonghyo Kim, Yutaka Sugihara et al. · 2021 · Clinical and Translational Medicine
53. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
    Alessandro Tubita, Zoe Lombardi, Ignazia Tusa, Azzurra Lazzeretti, Giovanna Sgrignani, Dimitri Papini, Alessio Menconi, Sinforosa Gagliardi, Matteo Lulli, Persio Dello Sbarba et al. · 2021 · Cancer Research
54. Emerging Themes in Mechanisms of Tumorigenesis by SWI/SNF Subunit Mutation
    Cheyenne A. Jones, William P. Tansey, April M. Weissmiller · 2022 · Epigenetics Insights
55. Comprehensive Genomic Characterization of Cutaneous Malignant Melanoma Cell Lines Derived from Metastatic Lesions by Whole-Exome Sequencing and SNP Array Profiling
    Ingrid Cifola, Alessandro Pietrelli, Clarissa Consolandi, Marco Severgnini, Eleonora Mangano, Vincenzo E. A. Russo, Gianluca De Bellis, Cristina Battaglia · 2013 · PLoS ONE
56. Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2
    Brooke M. Swalm, Sarah K. Knutson, Natalie M. Warholic, Lei Jin, Kevin W. Kuntz, Heike Keilhack, Jesse Joshua Smith, Roy M. Pollock, Mikel P. Moyer, Margaret Porter Scott et al. · 2014 · ACS Chemical Biology
57. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
    Meagan B. Ryan, Alexander J. Finn, Katherine H. Pedone, Nancy E. Thomas, Channing J. Der, Adrienne D. Cox · 2016 · Molecular Cancer Research
58. Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of <i>ATG5</i>
    García-Fernández, María, Karras, Panagiotis, Checinska, Agnieszka, Cañón, Estela, Calvo, Guadalupe T., Gómez-López, Gonzalo, Cifdaloz, Metehan, Colmenar, Angel, Espinosa-Hevia, Luis, Olmeda, David et al. · 2016 · Autophagy
59. Somatic Mutation of GRIN2A in Malignant Melanoma Results in Loss of Tumor Suppressor Activity via Aberrant NMDAR Complex Formation
    Todd D. Prickett, Brad J. Zerlanko, Victoria K. Hill, Jared J. Gartner, Nouar Qutob, Jiji Jiang, May Simaan, John R. Wunderlich, Jorge Silvio Gutkind, Steven A. Rosenberg et al. · 2014 · Journal of Investigative Dermatology
60. Cooperation between Noncanonical Ras Network Mutations
    Edward C. Stites, Paul C. Trampont, Lisa B. Haney, Scott F. Walk, Kodi S. Ravichandran · 2015 · Cell Reports
61. BRG 1 promotes survival of UV ‐irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene
    Srinivas Vinod Saladi, Philip G. Wong, Archit R. Trivedi, Himangi G. Marathe, Bridget Keenen, Shweta Aras, Zi‐Qi Liew, Vijayasaradhi Setaluri, Ivana L. de la Serna · 2013 · Pigment Cell & Melanoma Research
62. High‐throughput sequencing of the melanoma genome
    Manfred Kunz, Michael Dannemann, Janet F. Kelso · 2012 · Experimental Dermatology
63. Can we deconstruct cancer, one patient at a time?
    C. Anthony Blau, Effie Liakopoulou · 2012 · Trends in Genetics
64. Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
    Dragana Klinac, Elin Solomonovna Gray, Michael J. Millward, Mel R. Ziman · 2013 · Frontiers in Oncology
65. PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition
    Heidi L. Gold, Jordan Wengrod, Eleazar Vega‐Saenz de Miera, Ding Wang, Nathaniel H. Fleming, Lisa Sikkema, Tomas Kirchhoff, Tsivia Hochman, Judith D. Goldberg, Iman Osman et al. · 2013 · Molecular Cancer Research
66. Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression
    Blake Ferguson, Rosalyn R. Ram, Herlina Y. Handoko, Pamela Mukhopadhyay, Hans Konrad Muller, H. Peter Soyer, Grant Morahan, Graeme J. Walker · 2014 · Oncogene
67. Chromatin-regulating proteins as targets for cancer therapy
    Takahiro Oike, Hideaki Ogiwara, Napapat Amornwichet, Takashi Nakano, Takashi Kohno · 2014 · Journal of Radiation Research
68. Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma
    I. Aldiri, I. Ajioka, Bei-Si Xu, Jiakun Zhang, Xiang Chen, Claudia A. Benavente, David B. Finkelstein, Dianna A. Johnson, J. Akiyama, L. Pennacchio et al. · 2015 · Development
69. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
    M. Kiessling, Alessandra Curioni-Fontecedro, P. Samaras, S. Lang, M. Scharl, A. Aguzzi, Derek A. Oldrige, J. Maris, G. Rogler · 2016 · PLoS ONE
70. P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
    Mahamat Babagana, Sydney Johnson, Hannah Slabodkin, Wiam Bshara, Carl Morrison, Eugene Kandel · 2017 · Molecular Carcinogenesis
71. Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study
    Titus Josef Brinker, Dirk Schadendorf, Joachim Klode, Ioana Cosgarea, Alexander Rösch, Philipp Jansen, Ingo Stoffels, Benjamin Izar · 2017 · JMIR mhealth and uhealth
72. FOXQ1 controls the induced differentiation of melanocytic cells
    Archis Bagati, Anna Bianchi, Sudha Moparthy, Kateryna Kolesnikova, Emily E. Fink, Masha Kolesnikova, Matthew V. Roll, Peter Jowdy, David W. Wolff, Anthony Polechetti et al. · 2018 · Cell Death and Differentiation
73. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2
    Yubin Feng, Lanlan Li, Yan Zhi Du, Xiaoqing Peng, Feihu Chen · 2020 · Journal of Cellular and Molecular Medicine
74. Cutaneous melanomas attributable to ultraviolet radiation exposure by state
    Farhad Islami, Ann Goding Sauer, Kimberly D. Miller, Stacey A. Fedewa, Adair K. Minihan, Alan C. Geller, J. Leonard Lichtenfeld, Ahmedin Jemal · 2020 · International Journal of Cancer
75. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases
    Gino Kim In, Kelsey Anne Poorman, Michelle Edelman Saul, Steven J O'Day, Jeffrey M. Farma, Anthony J. Olszanski, Michael S. Gordon, Jacob Stephen Thomas, Burton Larry Eisenberg, Lawrence E. Flaherty et al. · 2020 · Oncotarget
76. Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma
    Renáta Váraljai, Susanne Horn, Antje Sucker, Daniela Piercianek, Verena Schmitt, Alexander Carpinteiro, Katrin Anne Becker, JULIA REIFENBERGER, Alexander Roesch, Jörg Felsberg et al. · 2021 · Cancers
77. The FBXO4 Tumor Suppressor Functions as a Barrier to Braf V600E -Dependent Metastatic Melanoma
    Eric K. Lee, Zhaorui Lian, Kurt P D'Andrea, Richard Letrero, Weiqi Sheng, Shujing Liu, John Alan Diehl, Dariusz Pytel, Olena Barbash, Lynn Mara Schuchter et al. · 2013 · Molecular and Cellular Biology
78. Looking beyond drivers and passengers in cancer genome sequencing data
    Subhajyoti De, Shridar Ganesan · 2016 · Annals of Oncology
79. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma
    Michael Olvedy, Julie C. Tisserand, Flavie Luciani, Bram Boeckx, Jasper Wouters, Sophie Lopez, Florian Rambow, Sara Aibar, Bernard Thienpont, Jasmine Barra et al. · 2017 · Journal of Clinical Investigation
80. Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC
    Luo, Chi, Sheng, Jinghao, Hu, Miaofen G., Haluska, Frank G., Cui, Rutao, Xu, Zhengping, Tsichlis, Philip N., Hu, Guo-Fu, Hinds, Philip W. · 2013 · Cancer Research
81. Computational methods for detecting cancer hotspots
    Emmanuel Martínez-Ledesma, David Flores, Víctor Treviño · 2020 · Computational and Structural Biotechnology Journal
82. Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma
    Thomas K. Ni, Sean F. Landrette, Robert D. Bjornson, Marcus Bosenberg, Tian Xu · 2013 · Proceedings of the National Academy of Sciences
83. WLS inhibits melanoma cell proliferation through the β‐catenin signalling pathway and induces spontaneous metastasis
    Pei‐Tzu Yang, Jamie N. Anastas, Rachel A. Toroni, Michi M. Shinohara, Jamie M. Goodson, Anja‐Katrin Bosserhoff, Andy J. Chien, Randall T. Moon · 2012 · EMBO Molecular Medicine
84. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker
    Johanne Lade‐Keller, Rikke Riber‐Hansen, Per Guldberg, Henrik Schmidt, Stephen Jacques Hamilton-Dutoit, Torben Steiniche · 2014 · Journal of Clinical Pathology
85. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma
    William R. Jeck, Joel S. Parker, Craig C. Carson, Janiel M. Shields, Maria J. Sambade, Eldon C. Peters, Christin Elizabeth Burd, Nancy E. Thomas, Derek Y. Chiang, Wenjing Liu et al. · 2014 · Pigment Cell & Melanoma Research
86. MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling cell cycle regulators, and Ets-1-mediated MMP-2 expression
    Seung‐Shick Shin, Sung‐Soo Park, Byung‐Doo Hwang, Won Tae Kim, Yung Hyun Choi, Wun‐Jae Kim, Sung‐Kwon Moon · 2016 · Oncology Reports
87. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
    Rakel Brendsdal Forthun, Randi Hovland, Cornelia Schuster, Hanne Eknes Puntervoll, Hans Petter Brodal, Heidi Maria Namløs, Lars Birger Aasheim, Leonardo A. Meza‐Zepeda, Bjørn Tore Gjertsen, Stian Knappskog et al. · 2019 · Scientific Reports
88. Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma
    Adriana M. Sanna, Katja Harbst, Iva Johansson, Gustav Boelsgaard Christensen, Martin Lauss, Shamik Mitra, Frida Rosengren, Jari Häkkinen, Johan Vallon‐Christersson, Hakan Lars Olsson et al. · 2019 · Pigment Cell & Melanoma Research
89. Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment
    Sean R. Porazinski, Ashleigh Parkin, Marina Pajic · 2020 · Advances in experimental medicine and biology
90. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
    Ling Mei Qian, Kun Chen, Changhong Wang, Zhen Chen, Zhiqiang Meng, Peng Wang · 2020 · Clinical Cancer Research
91. CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway
    Nancy T. Santiappillai, Shatha AbuHammad, Alison A. Slater, Laura Kirby, Grant A. McArthur, Karen E. Sheppard, Lorey K. Smith · 2021 · Cancers
92. Parkin Somatic Mutations Link Melanoma and Parkinson's Disease
    Lotan Levin, Shani Srour, Jared J. Gartner, Oxana Kapitansky, Nouar Qutob, Shani Dror, Tamar Golan, Roy Dayan, Ronen Brenner, Tamar Ziv et al. · 2016 · Journal of genetics and genomics/Journal of Genetics and Genomics
93. Mycobacterium bovis BCG in metastatic melanoma therapy
    Martha Ruiz-Benitez, Camila Bonemann Bender, Thaís Larré Oliveira, Kyle M. Schachtschneider, Tiago Veiras Collares, Fabiana K. Seixas · 2019 · Applied Microbiology and Biotechnology
94. Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines
    Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, Keiran S.M. Smalley · 2017 · Molecular Cancer Therapeutics
95. Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma
    Megan Kate Lyle, Georgina Venetia Long · 2013 · Journal of Clinical Oncology
96. Rac1 GTPase-deficient HeLa cells present reduced DNA repair, proliferation, and survival under UV or gamma irradiation
    Gisele Espinha, Juliana Harumi Osaki, Yuli Thamires Magalhães, Fábio Luís Forti · 2015 · Molecular and Cellular Biochemistry
97. β-Catenin Inhibitor ICAT Modulates the Invasive Motility of Melanoma Cells
    Mélanie J. Domingues, Florian Rambow, Bastien Job, Laura Papon, Wanguo Liu, Lionel Larue, Jacky Bonaventure · 2014 · Cancer Research
98. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation
    Hyeran Sung, Krishna Kanchi, Xue Wang, Kristen Suzanne Hill, Jane L. Messina, Ji‐Hyun Lee, Youngchul Kim, Nathan D. Dees, Li Ding, Jamie K. Teer et al. · 2016 · Oncotarget
99. AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1
    Hilary M. Sheppard, Vaughan Feisst, Jennifer Chen, Cristin Gregor Print, P. Rod Dunbar · 2015 · Melanoma Research
100. Distinct mutation accumulation rates among tissues determine the variation in cancer risk
     Dapeng Hao, Li Wang, Lijun Di · 2016 · Scientific Reports